|
Certificate of Incorporation |
|
BYLAWS OF THE COMPANY |
|
AIM admission document_Placing and admission to AIM |
|
Charter for the Compensation Committee of Board of Directors |
|
Charter for the Nominating Committee of Board of Directors |
|
SHAREHOLDERS WITH MORE THAN 3% HOLDINGS:
QIONG WANG, DIRECTOR (4.28%)
BO CHEN, CEO AND CHAIRMAN (4.14%)
A G BRANDT (7.25%)
TOTAL NUMBER OF SHARES NOT IN PUBLIC HANDS: 1,810,000
58.5% of the Company¡¯s shares are held as depositary receipts through Cede & Co in New York
Total shares outstanding as of June 11, 2014: 21,510,250 shares.
There are currently no restrictions on the trading of the AIM shares. |
|
Nominated Advisor (NOMAD) and Broker for AIM:
CHARLES STANLEY SECURITIES
25 LUKE STREET
LONDON
EC2A 4AR
Tel: +44 (0) 207 149 6000 |
|
Bodisen's independent auditor:
US: Clement C. W. Chan & Co.
UK: Clement C. W. Chan & Co.
|
|
Bodisen's legal counsel:
Sichenzia Ross Friedman Ference LLP.
|
|
Country of Incorporation
Bodisen Biotech, Inc., is a United States of America corporation, incorporated under the laws of the State of Delaware. As such, the rights of shareholders may be different than those of shareholders of a United Kingdom incorporated company.
|
|
Responsibility of the Board of Directors
The Board of Directors is responsible for the general direction and strategy of the Company, its performance, management and major financial decisions. The Board meets regularly to plan and monitor strategy, approve acquisitions and disposals, review managerial performance, examine capital and expenditures, approve budgets and deal with important financial matters. The Board assesses business risk exposure and performance based on strategy, budgetary goals and development programs. The Board also considers employee issues, key appointments and information for shareholders.
This information is disclosed in compliance with Rule 26 of the AIM Rules. |
General Information